Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial)
Andreas Dietz(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde), Michael Flentje(Universitätsklinikum Würzburg), P M Schneider(Klinikum Kassel), Jens Dreyhaupt(Universität Ulm), Volker Rudat(Saad Specialist Hospital), L. Pfreundner(University of Würzburg), Markus Heß(University of Nevada, Reno), Bernhard Vanselow(St. Vincentius-Kliniken), Thomas Kuhnt(Leipzig University), Wilfried Budach(Düsseldorf University Hospital), R. Engenhardt-Cabillic(Philipps University of Marburg), Maria Pritsch(Heidelberg University), Jochen A. Werner(Essen University Hospital), Rudolph Hagen(University of Würzburg), Michael Schröder(Klinikum Kassel), Ursula Schröder(University of Lübeck), H. P. Zenner(University of Tübingen), Peter K. Plinkert(Heidelberg University), H Eckel(Klinikum Klagenfurt), Marcus Niewald(Saarland University), Florian Hoppe(Klinikum Oldenburg), Bünzel Jens(Nordhausen University of Applied Sciences)
Cited by 53
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|550
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
|JAMA Oncology|2021|369
Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression
|Journal of Clinical Oncology|2005|347